Gilead third-quarter profit triples as sales more than double
October 28, 2014 at 16:27 PM EDT
Oct 28 (Reuters) - Gilead Sciences Inc, maker of $84,000 hepatitis C drug Sovaldi, on Tuesday said third quarter net profit more than tripled and product sales doubled, despite a dip in Sovaldi sales as doctors and patients awaited a recently approved combination pill.
